Global SUKIMA IDEAS

The KAYAKU spirit represents Nippon Kayaku Group's corporate
vision - the ultimate goal of all its corporate activities.
We fulfill our social responsibilities as part of our corporate efforts to realize
the KAYAKU spirit. These efforts are based on the standards of conduct
articulated in the Group Action Guidelines and in the Nippon Kayaku Group
Charter of Conduct and Code of Conduct.

What's New

2023/12/15
NIPPON KAYAKU ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH BIOCHEETAH FOR VECanDx TM IN JAPAN
2023/10/19
Updated information of sustainability
2023/10/18
Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication
2023/09/25
Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody. PDF
2022/11/16
Launch in Japan of Bevacizumab BS for I.V. Infusion 100mg・400mg “CTNK” ,an anti-VEGF humanized monoclonal antibody PDF

Investor Relations

Investor Relations News

2016 NIPPON KAYAKU 100th ANNIVERSARY
GO TO Website
PageTop
Our Business
R&D
Corporate Information
Global Netowork
Investor Relations
Sustainability